Testing lanthanide(III) complex stability using Eu(III) luminescence - documenting complex formation and stability in...

Area of Science:

• Coordination Chemistry
• Analytical Chemistry
• Radiopharmaceutical Chemistry

Background:

• Metal complexes are vital in medical diagnostics and therapy, with lanthanide(III) complexes already in clinical use.
• The inherent lability of metal complexes necessitates robust methods for assessing the stability of novel compounds.
• Established complexes like [Ln·DOTA]⁺ and [Ln·DTPA]^2- serve as benchmarks for stability, with DOTA comparable to peptides and DTPA forming highly stable complexes.

Purpose of the Study:

• To develop a rapid and straightforward method for evaluating the stability of lanthanide(III) complexes in solution.
• To assess the stability of novel ligand systems (Kryptofix221, Kryptofix222, and macropa) using europium(III) luminescence.
• To compare the performance of new complexes against known stable complexes like [Ln·DOTA]⁺ and [Ln·DTPA]^2-.

Main Methods:

• Utilized europium(III) luminescence as a direct reporter for complex formation and stability.
• Investigated the stability of complexes formed by Kryptofix221, Kryptofix222, and macropa with lanthanide(III) ions.
• Challenged the newly formed complexes with diethylenetriamine pentaacetic acid (DTPA) to assess their lability.
• Determined solvation numbers (q) to further support the stability assessments.

Main Results:

• Kryptofix221 and Kryptofix222 showed significant deviations from baseline complex formation, indicating poor complexation.
• Macropa formed a distinct europium(III) complex, but subsequent challenge with DTPA revealed its lability in solution.
• The results demonstrated that the tested novel ligand systems were less stable than anticipated or compared to benchmark complexes.

Conclusions:

• The developed europium(III) luminescence-based method is a robust and user-friendly tool for assessing lanthanide complex stability.
• The study highlights the importance of rigorous stability testing for new metal complexes intended for diagnostic or therapeutic applications.
• Novel ligand systems must be carefully evaluated to ensure they form sufficiently stable complexes under physiological conditions.